Landscapes / Companies
Inhibrx Biosciences, Inc not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
2
in active trials · 4 in all
Trials
4 active
6 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Inhibrx Biosciences · Elpiscience Biopharma |
Phase 2/3 | Dec 2029Phase 2/3 trial completes | ||
| Next date | Dec 2029 · Phase 2/3 trial completes | ||||
| Also tested for | Solid Tumor, Non-Small Cell Lung Cancer and 8 more | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2028Phase 1 trial completes | |||
| Next date | Dec 2028 · Phase 1 trial completes | ||||
| Also tested for | Ewing Sarcoma, Colorectal Adenocarcinoma and 1 more | ||||
| Open drug page | |||||
About
- No active trial
- ES101, INBRX-101/rhAAT-Fc
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021